fda compounded semaglutide decision US proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs Compounded Semaglutide & Tirzepatide 2025:

Weight loss through telehealth, which Klinic offers, matches FDA-approved medications like Wegovy, Zepbound, and Foundayo with your specific needs

Most patients using GLP-1 medications begin experiencing weight loss between 2-4 weeks of treatment initiation, with clinically meaningful reductions (5-10% body weight) typically emerging by 8-12 weeks

The most common side effect of GLP-1RAs is nausea and vomiting, which are hypothesized to result from inhibition of gastric emptying

Navigating Cost, Access, and Availability Knowing the clinical differences between tirzepatide and semaglutide is one thing, but for most people, the decision also comes down to practical factors like cost, insurance coverage, and availability